European Commission continues to probe for anti-competitive patent settlements
This article was originally published in SRA
Executive Summary
The number of pharmaceutical firms contriving illegal agreements to extend the monopoly of branded drugs appears to be coming down, but the European Commission has, for a second time, asked companies for information on patent settlements concluded between originators and generic medicines companies1. Companies are getting better at responding to the commission's inquiries, says Stephen Whitfield, an associate at the law firm, Taylor Wessing2.